Claims for Patent: 9,969,811

Summary for Patent: 9,969,811

Title:	Pertuzumab variants and evaluation thereof
Abstract:	The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.
Inventor(s):	Gennaro; Lynn A. (San Mateo, CA), Kao; Yung-Hsiang (San Mateo, CA), Zhang; Yonghua (Foster City, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	15/788,574
Patent Claims:	1. A method of treating a patient with cancer comprising administering a pharmaceutical composition to a cancer patient, wherein the pharmaceutical composition comprises: (a) a composition comprising Pertuzumab and unpaired cysteine variant thereof, wherein the unpaired cysteine variant comprises Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, and (b) and one or more pharmaceutically acceptable excipients. 2. The method of claim 1, wherein the cancer is breast cancer, gastric cancer, ovarian cancer, HER2-positive cancer, or low HER3 cancer.

Details for Patent 9,969,811

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	PERJETA	pertuzumab	Injection	125409	06/08/2012		2033-04-16